CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Brentuximab Vedotin (Adcetris) for Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine - Details

Project Number pCODR 10214
Brand Name Adcetris
Generic Name Brentuximab Vedotin
Strength 50 mg
Tumour Type Lymphoma
Indication Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)
Funding Request For the treatment of previously untreated patients with Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD).
Review Status Under Review
Pre Noc Submission No
NOC Date May 2, 2019
Manufacturer Seattle Genetics, Inc.
Sponsor Seattle Genetics, Inc.
Submission Date April 2, 2020
Submission Deemed Complete April 21, 2020
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ April 17, 2020
Check-point meeting (target date) June 3, 2020
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.